title: Anti-inflammatory activity of N-(3-florophenyl)ethylcaffeamide in mice.
abstract: In this study, we evaluated the anti-inflammatory activity of one synthetic product, N-(3-Florophenyl)ethylcaffeamide (abbrev. FECA), by using animal model of λ-carrageenan-induced paw edema in mice. The anti-inflammatory mechanism of FECA was determined by measuring the levels of cyclooxygenase-2 (COX-2), nitric oxide (NO), tumor necrosis factor (TNF-α), interleukin-1β (IL-1β), and malondialdehyde (MDA) in the edema paw tissue, and the activities of superoxide dismutase (SOD), glutathione peroxidase (GPx), and glutathione reductase (GRd) in the liver. The results showed that FECA reduced the paw edema at three, four and five hours after λ-carrageenan administration. The levels of COX-2, NO, TNF-α, and MDA in the λ-carrageenan-induced edema paws were reduced and the activities of SOD, GPx, and GRd in liver tissues were raised by FECA. These results suggested that FECA possessed anti-inflammatory activities and the anti-inflammatory mechanisms might be related to the decrease of the levels of COX-2, NO, and TNF-α in inflamed tissues and the increase in the MDA level by increasing the activities of SOD, GPx, and GRd.
authors.affiliation: School of Pharmacy, College of Pharmacy, China Medical University, Taichung 404, Taiwan. ljc@mail.cmu.edu.tw
authors.forename: Jung-Chun
authors.initials: JC
authors.lastname: Liao
authors.forename: Jen-Chieh
authors.initials: JC
authors.lastname: Tsai
authors.forename: Wen-Huang
authors.initials: WH
authors.lastname: Peng
authors.forename: Yung-Jia
authors.initials: YJ
authors.lastname: Chiu
authors.forename: Ping-Jyun
authors.initials: PJ
authors.lastname: Sung
authors.forename: Minoru
authors.initials: M
authors.lastname: Tsuzoki
authors.forename: Yueh-Hsiung
authors.initials: YH
authors.lastname: Kuo
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D002109:Caffeic Acids / Q000494:pharmacology*; D002351:Carrageenan; D051546:Cyclooxygenase 2 / Q000032:analysis / Q000378:metabolism; D004487:Edema / Q000139:chemically induced / Q000188:drug therapy*; D005979:Glutathione Peroxidase / Q000378:metabolism; D005980:Glutathione Reductase / Q000378:metabolism; D007249:Inflammation / Q000188:drug therapy*; D053583:Interleukin-1beta / Q000032:analysis / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008297:Male; D008315:Malondialdehyde / Q000032:analysis / Q000378:metabolism; D051379:Mice; D008813:Mice, Inbred ICR; D009569:Nitric Oxide / Q000032:analysis / Q000378:metabolism; D013482:Superoxide Dismutase / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis / Q000378:metabolism; D034941:Upper Extremity
chemical_list: D000893:Anti-Inflammatory Agents; D002109:Caffeic Acids; D053583:Interleukin-1beta; C587493:N-(3-fluorophenyl)ethylcaffeamide; D014409:Tumor Necrosis Factor-alpha; D009569:Nitric Oxide; D008315:Malondialdehyde; D002351:Carrageenan; D005979:Glutathione Peroxidase; C077623:Ptgs2 protein, mouse; D051546:Cyclooxygenase 2; D013482:Superoxide Dismutase; D005980:Glutathione Reductase